Bessede et al. reported that NSCLC patients with high expression of Trop-2 had a poorer efficacy of immunotherapy than those with low expression (median PFS, 2.5 vs. 4.1 months, p < 0.001) [10]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.